Updates and Advances in the Management of HS : Episode 5
SUNSHINE and SUNRISE Trials in HS
An expert in dermatology reviews the phase 3 SUNSHINE and SUNRISE trials evaluating the use of secukinumab given in 2-week intervals in patients with HS and shares clinical pearls for managing the condition.
EP: 1.Overview of Hidradenitis Suppurativa (HS): A Multifactorial Disease
EP: 2.Approaching Treatment and Addressing Unmet Needs for Mild-to-Moderate HS
EP: 3.Role of Immunomodulation in HS Treatment
EP: 4.Emerging Agents for the Management of HS
Now Viewing
EP: 5.SUNSHINE and SUNRISE Trials in HS
EP: 6.Overview and Diagnosis of Hidradenitis Suppurativa (HS)
EP: 7.Role of TNF-α Inhibitors in Moderate-to-Severe HS Treatment
EP: 8.Unmet Needs and Emerging Therapies in HS
EP: 9.Clinical Pearls for the Management of HS
EP: 10.Quality of Life for Patients With Hidradenitis Suppurativa (HS)
EP: 11.Diagnosis of HS
EP: 12.Treatment Options for HS
EP: 13.Emerging Therapy for Patients With HS
EP: 14.Clinical Pearls for Providers Treating HS
Related Videos
Related Content
